Niagen Bioscience, Inc. NAGE
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 27.19M | 29.79M | 31.47M | 33.84M | 33.99M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.19M | 29.79M | 31.47M | 33.84M | 33.99M |
| Cost of Revenue | 10.09M | 10.47M | 11.50M | 12.14M | 12.06M |
| Gross Profit | 17.11M | 19.31M | 19.98M | 21.70M | 21.93M |
| SG&A Expenses | 16.90M | 17.10M | 16.92M | 17.89M | 15.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.78M | 29.09M | 29.90M | 31.74M | 29.75M |
| Operating Income | -1.59M | 700.00K | 1.58M | 2.10M | 4.24M |
| Income Before Tax | -1.17M | 1.07M | 6.74M | 4.42M | 4.80M |
| Income Tax Expenses | -- | 106.00K | 417.00K | 292.00K | 222.00K |
| Earnings from Continuing Operations | -1.17M | 963.00K | 6.32M | 4.13M | 4.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.17M | 963.00K | 6.32M | 4.13M | 4.58M |
| EBIT | -1.59M | 700.00K | 1.58M | 2.10M | 4.24M |
| EBITDA | -1.30M | 991.00K | 1.87M | 2.30M | 4.43M |
| EPS Basic | -0.01 | 0.01 | 0.08 | 0.05 | 0.06 |
| Normalized Basic EPS | -0.01 | 0.01 | 0.02 | 0.02 | 0.04 |
| EPS Diluted | -0.01 | 0.01 | 0.07 | 0.05 | 0.05 |
| Normalized Diluted EPS | -0.01 | 0.01 | 0.01 | 0.02 | 0.03 |
| Average Basic Shares Outstanding | 79.15M | 79.32M | 79.92M | 78.97M | 79.78M |
| Average Diluted Shares Outstanding | 79.15M | 82.50M | 84.57M | 84.44M | 86.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |